BACKGROUND AND OBJECTIVES: The microvascular circulation plays an important role in bone health. This study examines whether albuminuria, a marker of renal microvascular disease, is associated with incident hip and pelvic fractures. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study reanalyzed data from the Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial/Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease trials, which examined the impact of renin angiotensin system blockade on cardiovascular outcomes (n=28,601). Albuminuria was defined as an albumin-to-creatinine ratio≥30 mg/g (n=4597). Cox proportional hazards models were used to determine the association of albuminuria with fracture risk adjusted for known risk factors for fractures, estimated GFR, and rapid decline in estimated GFR (≥5%/yr). RESULTS: There were 276 hip and pelvic fractures during a mean of 4.6 years of follow-up. Participants with baseline albuminuria had a significantly increased risk of fracture compared with participants without albuminuria (unadjusted hazard ratio=1.62 [1.22, 2.15], P<0.001; adjusted hazard ratio=1.36 [1.01, 1.84], P=0.05). A dose-dependent relationship was observed, with macroalbuminuria having a large fracture risk (unadjusted hazard ratio=2.01 [1.21, 3.35], P=0.007; adjusted hazard ratio=1.71 [1.007, 2.91], P=0.05) and microalbuminuria associating with borderline or no statistical significance (unadjusted hazard ratio=1.52 [1.10, 2.09], P=0.01; adjusted hazard ratio=1.28 [0.92, 1.78], P=0.15). Estimated GFR was not a predictor of fracture in any model, but rapid loss of estimated GFR over the first 2 years of follow-up predicted subsequent fracture (adjusted hazard ratio=1.47 [1.05, 2.04], P=0.02). CONCLUSIONS:Albuminuria, especially macroalbuminuria, and rapid decline of estimated GFR predict hip and pelvic fractures. These findings support a theoretical model of a relationship between underlying causes of microalbuminuria and bone disease.
RCT Entities:
BACKGROUND AND OBJECTIVES: The microvascular circulation plays an important role in bone health. This study examines whether albuminuria, a marker of renal microvascular disease, is associated with incident hip and pelvic fractures. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study reanalyzed data from the Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial/Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease trials, which examined the impact of renin angiotensin system blockade on cardiovascular outcomes (n=28,601). Albuminuria was defined as an albumin-to-creatinine ratio≥30 mg/g (n=4597). Cox proportional hazards models were used to determine the association of albuminuria with fracture risk adjusted for known risk factors for fractures, estimated GFR, and rapid decline in estimated GFR (≥5%/yr). RESULTS: There were 276 hip and pelvic fractures during a mean of 4.6 years of follow-up. Participants with baseline albuminuria had a significantly increased risk of fracture compared with participants without albuminuria (unadjusted hazard ratio=1.62 [1.22, 2.15], P<0.001; adjusted hazard ratio=1.36 [1.01, 1.84], P=0.05). A dose-dependent relationship was observed, with macroalbuminuria having a large fracture risk (unadjusted hazard ratio=2.01 [1.21, 3.35], P=0.007; adjusted hazard ratio=1.71 [1.007, 2.91], P=0.05) and microalbuminuria associating with borderline or no statistical significance (unadjusted hazard ratio=1.52 [1.10, 2.09], P=0.01; adjusted hazard ratio=1.28 [0.92, 1.78], P=0.15). Estimated GFR was not a predictor of fracture in any model, but rapid loss of estimated GFR over the first 2 years of follow-up predicted subsequent fracture (adjusted hazard ratio=1.47 [1.05, 2.04], P=0.02). CONCLUSIONS:Albuminuria, especially macroalbuminuria, and rapid decline of estimated GFR predict hip and pelvic fractures. These findings support a theoretical model of a relationship between underlying causes of microalbuminuria and bone disease.
Authors: James F Griffith; David K W Yeung; Gregory E Antonio; Francis K H Lee; Athena W L Hong; Samuel Y S Wong; Edith M C Lau; Ping Chung Leung Journal: Radiology Date: 2005-07-29 Impact factor: 11.105
Authors: Rhonda D Prisby; Michael W Ramsey; Brad J Behnke; James M Dominguez; Anthony J Donato; Matthew R Allen; Michael D Delp Journal: J Bone Miner Res Date: 2007-08 Impact factor: 6.741
Authors: Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher Journal: Am Heart J Date: 2004-07 Impact factor: 4.749
Authors: Joshua I Barzilay; Do Peterson; Mary Cushman; Susan R Heckbert; Jie J Cao; Caroline Blaum; Russell P Tracy; Ronald Klein; David M Herrington Journal: Am J Kidney Dis Date: 2004-07 Impact factor: 8.860
Authors: Anda Gonciulea; Ruibin Wang; Keri N Althoff; Michelle M Estrella; Deborah E Sellmeyer; Frank J Palella; Jordan E Lake; Lawrence A Kingsley; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Tamara Isakova; Timothy E Craven; Julia J Scialla; Thomas L Nickolas; Adrian Schnall; Joshua Barzilay; Ann V Schwartz Journal: Bone Date: 2015-04-30 Impact factor: 4.398
Authors: Howard A Fink; Tien N Vo; Lisa Langsetmo; Joshua I Barzilay; Jane A Cauley; John T Schousboe; Eric S Orwoll; Muna T Canales; Areef Ishani; Nancy E Lane; Kristine E Ensrud Journal: J Bone Miner Res Date: 2017-02-21 Impact factor: 6.741
Authors: Petra Bůžková; Joshua I Barzilay; Howard A Fink; John A Robbins; Jane A Cauley; Annette L Fitzpatrick Journal: J Clin Endocrinol Metab Date: 2014-08-22 Impact factor: 5.958
Authors: Natalie Daya; Annie Voskertchian; Andrea L C Schneider; Shoshana Ballew; Mara McAdams DeMarco; Josef Coresh; Lawrence J Appel; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2015-08-04 Impact factor: 8.860
Authors: J I Barzilay; P Bůžková; Z Chen; I H de Boer; L Carbone; N N Rassouli; H A Fink; J A Robbins Journal: Osteoporos Int Date: 2013-05-24 Impact factor: 4.507
Authors: J I Barzilay; P Bůžková; H A Fink; J A Cauley; J A Robbins; P S Garimella; D I Jalal; K J Mukamal Journal: Osteoporos Int Date: 2016-06-01 Impact factor: 4.507